Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KQB198 in advanced hematologic malignancies
NL-OMON60352Phase 1Completed
- Sponsor
- Kumquat Biosciences
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KQB198 in hematopoietic malignancies (2 arms), sponsored by Kumquat Biosciences. Primary endpoint: Primary endpoint(s). Started Jul 2025; status: completed.
02
Drugs
KQB198
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON60352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60352.